HomeAI · summaries
Storia in 2 fonti
HLB resolves issues behind FDA setback for novel liver cancer drug - The Korea Times
The U.S. Food and Drug Administration (FDA) has determined that the inspection findings behind its rejection of HLB's liver cancer drug Rivoceranib...
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
koreaherald.com
FDA hurdle cleared for liver cancer drug application: HLB
HLB said Wednesday it received a Voluntary Action Indicated notice from the US Food and Drug Administration after the American authorities had conducted an on-s
- ·
koreatimes.co.kr
HLB resolves issues behind FDA setback for novel liver cancer drug - The Korea Times
The U.S. Food and Drug Administration (FDA) has determined that the inspection findings behind its rejection of HLB's liver cancer drug Rivoceranib...